BioRestorative Therapies (BRTX) 10-Q 15 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 11, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1,505,497
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,421,326
Trading Symbol	BRTX
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current Assets:
Cash	$ 8,857	$ 31,822
Accounts receivable	7,000	6,000
Prepaid expenses and other current assets	22,366	35,578
Total Current Assets	38,223	73,400
Property and equipment, net	463,025	508,594
Intangible assets, net	945,121	963,845
Security deposit	34,176	34,176
Total Assets	1,480,545	1,580,015
Current Liabilities:
Accounts payable	2,284,013	2,283,981
Accrued expenses and other current liabilities	1,670,859	1,574,659
Accrued interest	164,117	127,375
Current portion of notes payable, net of debt discount of $81,790 and $152,720 at March 31, 2017 and December 31, 2016, respectively	1,940,149	1,858,845
Total Current Liabilities	6,059,138	5,844,860
Accrued expenses, non-current portion		430,000
Accrued interest, non-current portion	5,447	7,681
Notes payable, non-current portion, net of debt discount of $2,374 and $27,244 at March 31, 2017 and December 31, 2016, respectively	137,626	297,756
Total Liabilities	6,202,211	6,580,297
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares; none issued and outstanding at March 31, 2017 and December 31, 2016
Common stock, $0.001 par value; Authorized, 30,000,000 shares; Issued and outstanding 5,331,047 and 4,699,035 shares at March 31, 2017 and December 31, 2016, respectively	5,331	4,699
Additional paid-in capital	40,018,555	36,954,817
Accumulated deficit	(44,745,552)	(41,959,798)
Total Stockholders' Deficiency	(4,721,666)	(5,000,282)
Total Liabilities and Stockholders' Deficiency	$ 1,480,545	$ 1,580,015

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Notes payable current, debt discount	$ 81,790	$ 152,720
Notes payable non-current, debt discount	$ 2,374	$ 27,244
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares Issued	5,331,047	4,699,035
Common stock, shares Outstanding	5,331,047	4,699,035

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenues	$ 7,000	$ 9,125
Cost of sales		10
Gross Profit	7,000	9,115
Operating Expenses
Marketing and promotion	29,070	22,517
Consulting	464,135	284,807
Research and development	805,853	866,044
General and administrative	1,197,313	902,881
Total Operating Expenses	2,496,371	2,076,249
Loss From Operations	(2,489,371)	(2,067,134)
Other Expense
Interest expense	(97,801)	(42,840)
Amortization of debt discount	(132,742)	(337,021)
Loss on extinguishment of notes payable, net	(61,340)	(11,847)
Warrant modification expense	(4,500)	(28,486)
Total Other Expense	(296,383)	(420,194)
Net Loss	$ (2,785,754)	$ (2,487,328)
Net Loss Per Share - Basic and Diluted	$ (0.56)	$ (0.69)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	4,985,297	3,619,813

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Deficiency (Unaudited)	3 Months Ended
	Mar. 31, 2017USD ($)shares
Common Stock [Member]
Balance	$ 4,699
Balance, shares | shares	4,699,035
Shares and warrants issued for cash	$ 303
Shares and warrants issued for cash, shares | shares	303,335
Exercise of warrants for purchase of common stock	$ 50
Exercise of warrants for purchase of common stock, shares | shares	50,000
Conversion of notes payable and accrued interest into common stock	$ 26
Conversion of notes payable and accrued interest into common stock, shares | shares	26,207
Shares and warrants issued in exchange of notes payable and accrued interest	$ 96
Shares and warrants issued in exchange of notes payable and accrued interest, shares | shares	95,802
Shares issued in satisfaction of accrued services	$ 157
Shares issued in satisfaction of accrued services, shares | shares	156,668
Warrants issued or modified as debt discount in connection with notes payable
Warrants issued or modified as debt discount in connection with notes payable, shares | shares
Stock-based compensation: - options and warrants
Balance	$ 5,331
Balance, shares | shares	5,331,047
Additional Paid-In Capital [Member]
Balance	$ 36,954,817
Shares and warrants issued for cash	909,697
Exercise of warrants for purchase of common stock	174,950
Conversion of notes payable and accrued interest into common stock	68,385
Shares and warrants issued in exchange of notes payable and accrued interest	348,646
Shares issued in satisfaction of accrued services	568,547
Warrants issued or modified as debt discount in connection with notes payable	33,620
Warrant modifications	4,500
Stock-based compensation: - options and warrants	955,393
Balance	40,018,555
Accumulated Deficit [Member]
Balance	(41,959,798)
Shares and warrants issued for cash
Exercise of warrants for purchase of common stock
Conversion of notes payable and accrued interest into common stock
Shares and warrants issued in exchange of notes payable and accrued interest
Shares issued in satisfaction of accrued services
Warrants issued or modified as debt discount in connection with notes payable
Warrant modifications
Stock-based compensation: - options and warrants
Net loss	(2,785,754)
Balance	(44,745,552)
Balance	(5,000,282)
Shares and warrants issued for cash	$ 910,000
Shares and warrants issued for cash, shares | shares	303,335
Exercise of warrants for purchase of common stock	$ 175,000
Conversion of notes payable and accrued interest into common stock	68,411
Shares and warrants issued in exchange of notes payable and accrued interest	348,742
Shares issued in satisfaction of accrued services	568,704
Warrants issued or modified as debt discount in connection with notes payable	33,620
Warrant modifications	4,500
Stock-based compensation: - options and warrants	955,393
Net loss	(2,785,754)
Balance	$ (4,721,666)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash Flows From Operating Activities
Net loss	$ (2,785,754)	$ (2,487,328)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	132,742	337,021
Accretion of interest expense	41,052	2,916
Depreciation and amortization	64,293	62,392
Stock-based compensation	955,393	411,618
Loss on extinguishment of note payables, net	61,340	11,847
Loss on settlement of payables	98,704
Warrant modification expense	4,500	28,486
Changes in operating assets and liabilities:
Accounts receivable	(1,000)	84,375
Prepaid expenses and other current assets	13,212	7,288
Accounts payable	15,032	(265,091)
Accrued interest, expenses and other current liabilities	181,521	88,641
Total Adjustments	1,566,789	769,493
Net Cash Used In Operating Activities	(1,218,965)	(1,717,835)
Cash Flows From Investing Activities
Purchases of property and equipment		(89,865)
Net Cash Used In Investing Activities		(89,865)
Cash Flows From Financing Activities
Proceeds from notes payable	200,000	325,000
Repayments of notes payable	(74,000)	(103,500)
Advances from an officer	30,015	46,030
Repayments of advances from an officer and a director	(45,015)	(104,560)
Proceeds from exercise of warrants	175,000	212,898
Sales of common stock and warrants for cash	910,000	1,618,372
Net Cash Provided By Financing Activities	1,196,000	1,994,240
Net (Decrease) Increase In Cash	(22,965)	186,540
Cash - Beginning	31,822	166,555
Cash - Ending	8,857	353,095
Supplemental Disclosures of Cash Flow Information:
Interest	11,000	10,000
Non-cash investing and financing activities:
Warrants modification expense	4,500	28,486
Shares and warrants issued or modified as debt discount in connection with notes payable	33,620	31,009
Shares and warrants issued in exchange for notes payable and accrued interest	348,742	177,649
Conversion of notes payable and accrued interest into common stock	68,411	157,370
Shares issued in satisfaction of accrued consulting and director services	568,704	2,333
Beneficial conversion features set up as debt discount		$ 215,446

Business Organization and Natur

Business Organization and Nature of Operations	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization and Nature of Operations	Note 1 – Business Organization and Nature of Operations BioRestorative Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (“Stem Pearls”). Stem Cell Cayman Ltd. (“Cayman”), which was formed in the Cayman Islands as a wholly owned subsidiary of the Company, was dissolved during the three months ended March 31, 2017. BioRestorative Therapies, Inc. and its subsidiaries are referred to collectively as “BRT” or the “Company” (See Note 3 – Summary of Significant Accounting Policies – Principles of Consolidation). BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com BRTX-100 in vitro The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of March 31, 2017 and for the three months ended March 31, 2017 and 2016. The results of operations for the three months ended March 31, 2017 are not necessarily indicative of the operating results for the full year ending December 31, 2017 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2016 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on March 22, 2017.

Going Concern and Management's

Going Concern and Management's Plans	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Plans	Note 2 – Going Concern and Management’s Plans As of March 31, 2017, the Company had a working capital deficiency and a stockholders’ deficiency of $6,020,915 and $4,721,666, respectively. During the three months ended March 31, 2017 and 2016, the Company incurred net losses of $2,785,754 and $2,487,328, respectively. These conditions indicate that there is substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the filing date of this report. The Company’s primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to March 31, 2017, the Company has received aggregate equity proceeds and debt proceeds of $54,000 and $325,000, respectively, debt and accrued interest of $140,000 and $6,137, respectively, has been converted into or exchanged for common stock, and the due date for the repayment of $462,250 of debt has been extended to dates between June 2017 and October 2017. As a result, the Company expects to have the cash required to fund its operations through mid-June 2017. While there can be no assurance that it will be successful, the Company is in negotiations to raise additional capital. As of the filing date of this report, the Company has notes payable with an aggregate principal balance of $252,500 which are past due. The Company is currently in the process of negotiating extensions or discussing conversions to equity with respect to these notes. However, there can be no assurance that the Company will be successful in extending or converting these notes. See Note 8 – Subsequent Events for additional details.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. As discussed above, Cayman, which had no material assets, liabilities or operations (other than intercompany balances) and is no longer needed to facilitate certain financings, was dissolved during the three months ended March 31, 2017. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net loss. Concentrations One license and the related royalties comprised substantially all of the Company’s revenue during the three months ended March 31, 2017 and 2016. See Revenue Recognition below. Revenue Recognition The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after estimating potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. During the three months ended March 31, 2017 and 2016, the Company recognized revenue related to sales of Stem Pearls skincare products of $0 and $125, respectively. In November 2015, the Company and a stem cell treatment company (“SCTC”) entered into an amendment to a January 27, 2012 license agreement between them. Pursuant to the amendment, effective November 30, 2015, the Company granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States, certain intellectual property related to stem cell disc procedures (that originally was licensed to the Company by the SCTC pursuant to the January 27, 2012 license agreement). In consideration of the sublicense, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. During the three months ended March 31, 2017 and 2016, the Company recognized $7,000 and $9,000, respectively, of revenue related to the Company’s sublicense agreement. Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: March 31, 2017 2016 Options 2,168,950 1,345,450 Warrants 3,513,956 2,275,036 Convertible notes 136,360 68,467 Total potentially dilutive shares 5,819,266 3,688,953 Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) are registered, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed. Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation – Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following: March 31, 2017 December 31, 2016 Credit card payable $ 1,607 $ 1,778 Accrued payroll 888,387 1,105,293 Accrued research and development expenses 411,175 581,175 Accrued general and administrative expenses 318,893 263,468 Deferred rent 50,797 52,945 Total accrued expenses $ 1,670,859 $ 2,004,659 During the three months ended March 31, 2017, the Company received non-interest bearing advances in the amount of $30,015 from an officer of the Company and repaid an aggregate of $45,015 of non-interest bearing advances from a director and an officer of the Company. Effective March 1, 2017, the Company entered into an exchange agreement with the Chairman of the Company’s Scientific Advisory Board, pursuant to which an aggregate of $175,000 of accrued consulting fees were exchanged for 58,334 shares of common stock of the Company and, in consideration thereof, the Company issued to such person an immediately vested five-year warrant for the purchase of 58,334 shares of common stock of the Company at an exercise price of $4.00 per share. The common stock and warrants had an aggregate grant date value of $211,752 and, as a result, the Company recorded a loss on settlement of payables of $36,752. Effective March 1, 2017, the Company entered into exchange agreements with four non-employee directors of the Company, pursuant to which an aggregate of $265,000 of accrued director fees were exchanged for an aggregate of 88,334 shares of common stock of the Company and, in consideration thereof, the Company issued to the directors immediately vested five-year warrants for the purchase of an aggregate of 88,334 shares of common stock of the Company at an exercise price of $4.00 per share. The aggregate value of shares and warrants were $320,652, and accordingly the Company recorded a loss on settlement of payables of $55,652. See Note 6 – Commitments and Contingencies – Consulting Agreements for details regarding an additional exchange of accrued consulting fees for shares of common stock and warrants.

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Notes Payable	Note 5 – Notes Payable A summary of the notes payable activity during the three months ended March 31, 2017 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, December 31, 2016 $ 697,500 $ 390,000 [1] $ 1,249,065 $ (179,964 ) $ 2,156,601 Issuances - - 242,000 - 242,000 Exchanges for equity (97,500 ) - (182,500 ) - (280,000 ) Conversions to equity - (65,000 ) - - (65,000 ) Repayments (50,000 ) - (24,000 ) - (74,000 ) Recognition of debt discount - - - (75,620 ) (75,620 ) Accretion of interest expense - - - 41,052 41,052 Amortization of debt discount - - - 132,742 132,742 Outstanding, March 31, 2017 $ 550,000 $ 325,000 [1] $ 1,284,565 $ (81,790 ) $ 2,077,775 [1] As of March 31, 2017 and December 31, 2016, a designated portion of convertible notes with an aggregate principal balance of $325,000 and $390,000, respectively, were convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $256,250 and $296,250 of principal into shares of common stock at March 31, 2017 and December 31, 2016, respectively, at the same conversion price. Related Party Notes As of March 31, 2017 and December 31, 2016, related party notes consisted of notes payable issued to certain directors of the Company and the Tuxis Trust (the “Trust”). A director and principal shareholder of the Company serves as the trustee of Trust, which was established for the benefit of his immediate family. Convertible Notes and Other Notes Issuances On January 3, 2017, the Company issued a lender a six-month note payable in the principal amount of $242,000, which bears no interest, for cash proceeds of $200,000. The $42,000 difference was recorded as an original issue discount and is being amortized over the term of the note. In connection with the issuance of this promissory note, the Company issued the lender an immediately vested five-year warrant to purchase 20,000 shares of common stock an exercise price of $4.00 per share. The relative fair value of the warrant of $28,730 has been recorded as a debt discount and is being amortized over the term of the note. Conversions, Exchanges and Other During the three months ended March 31, 2017, the Company and certain lenders agreed to exchange certain notes payable with an aggregate principal balance of $280,000 and aggregate accrued interest of $7,402 into an aggregate of 95,802 shares of common stock and immediately vested five-year warrants to purchase an aggregate of 95,802 shares of common stock at an exercise price of $4.00 per share. In addition, in consideration of the exchange by one lender, the Company agreed to extend the expiration dates of certain warrants held by the lender for the purchase of an aggregate of 18,000 shares of common stock of the Company at an exercise price of $4.00 per share, from expiration dates ranging from April 27, 2021 to January 31, 2022 to a new expiration date of February 8, 2022. The common stock, warrants, and warrant modification (which represents the incremental value of the modified warrant as compared to the original warrant value, both valued as of the modification date) had an aggregate exchange date value of $348,742 and, as a result, the Company recorded a loss on extinguishment of notes payable of $61,340. During the three months ended March 31, 2017, the Company elected to convert certain convertible notes with an aggregate principal balance of $65,000 and aggregate accrued interest of $3,411 into an aggregate of 26,207 shares of common stock at conversion prices ranging from $2.51 to $2.77 per share. During the three months ended March 31, 2017, the Company and certain lenders agreed to extend notes payable with an aggregate principal balance of $322,000 from maturity dates ranging between January 2017 to February 2017 to new maturity dates ranging from March 2017 to April 2017. In connection with one of the extensions, the Company issued the lender a five-year, immediately vested warrant to purchase 3,000 shares of common stock at an exercise price of $4.00 per share. The grant date fair value of the warrant of $4,890 has been recorded as debt discount and is being amortized over the term of the note. During the three months ended March 31, 2017, the Company repaid an aggregate principal amount of $74,000 of notes payable.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Consulting Agreements Business Advisory Services In March 2017, a February 2011 agreement for business advisory services that had expired on December 31, 2016 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of January 1, 2017 and provides for an expiration date of December 31, 2017. In consideration of the extension of the term of the consulting agreement, the Company issued to the consultant an immediately vested five-year warrant for the purchase of 25,000 shares of common stock of the Company at an exercise price of $4.00 per share. The aggregate grant date value of the warrant of $40,763 was recognized immediately as stock-based compensation expense which is reflected as consulting expense in the unaudited condensed consolidated financial statements. Concurrently, the Company entered into an exchange agreement with the consultant pursuant to which $30,000 of accrued consulting fees were exchanged for 10,000 shares of common stock of the Company and, in consideration thereof, the Company issued to the consultant an immediately vested five-year warrant for the purchase of 10,000 shares of common stock of the Company at an exercise price of $4.00 per share. The aggregate value of shares and warrant were $36,300, and accordingly the Company recorded a loss on settlement of payables of $6,300. Operating Lease Rent expense amounted to $32,000 and $33,000 for the three months ended March 31, 2017 and 2016, respectively. Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Employment Agreements In February 2017 and March 2017, the Company’s Compensation Committee and Board of Directors, respectively, approved the following associated with performance-based cash bonuses for certain of the Company’s officers and current employees: (i) new performance-based cash bonuses payable for the year ending December 31, 2017 such that an aggregate of up to $402,500 could be earned for such year pursuant to the satisfaction of such goals; and (ii) the amendment of the performance-based cash bonuses for the year ended December 31, 2016 such that an aggregate of up to $345,250 could be earned for such year pursuant to the satisfaction of such goals. Also, pursuant to the amendment of the performance-based cash bonuses, the Company’s officers and certain employees achievement date of 2016 milestones has been extended from January 31, 2017 to July 31, 2017. As of December 31, 2016, the Company accrued approximately $191,000 for 2016 bonus milestones which were achieved and approximately $100,000 for 2016 bonus milestones which were probable to be achieved. As of March 31, 2017, the Company accrued approximately $255,000 for 2016 bonus milestones which were achieved, approximately $53,000 for 2016 bonus milestones which are probable to be achieved and approximately $99,000 for 2017 bonus milestones which are probable to be achieved.

Stockholders' Deficiency

Stockholders' Deficiency	3 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders’ Deficiency	Note 7 – Stockholders’ Deficiency Common Stock and Warrant Offerings During the three months ended March 31, 2017, the Company issued an aggregate of 303,335 shares of common stock and five-year immediately vested warrants to purchase an aggregate of 313,335 shares of common stock at an exercise price of $4.00 to investors for aggregate gross proceeds of $910,000. The warrants had an aggregate grant date fair value of $510,735. Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0% to 5% for options granted during the three months ended March 31, 2017 and 2016. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Warrant Modification and Exercise During the three months ended March 31, 2017, with respect to a warrant held by an investor, the Company agreed that (i) the conditions to the exercisability of the warrant for tranches to purchase an aggregate of 35,000 shares were eliminated, such that the entire warrant to purchase 50,000 shares of common stock was exercisable, and (ii) the exercise price of the warrant was reduced from an exercise price of $30.00 per share to $3.50 per share. Concurrent with the modification of the warrant, the investor exercised the warrant in full for aggregate gross proceeds to the Company of $175,000. The Company recognized a warrant modification charge of $4,500 during the three months ended March 31, 2017, which represents the incremental value of the modified warrants as compared to the original warrants, both valued as of the respective modification dates which is reflected in warrant modification expense in the unaudited condensed consolidated statement of operations . Stock Warrants In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Three Months Ended March 31, 2017 2016 Risk free interest rate 2.14% - 2.33 % 0.44% - 1.47 % Expected term (years) 5.00 0.67-5.00 Expected volatility 132 % 124 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the three months ended March 31, 2017 and 2016 was approximately $1.63 and $0.89 per share, respectively. The Company recorded stock–based compensation expense of $40,763 and $0 during the three months ended March 31, 2017 and 2016, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the unaudited condensed consolidated statements of operations. As of March 31, 2017, there was no unrecognized stock-based compensation expense related to stock warrants. A summary of the warrant activity during the three months ended March 31, 2017 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2016 2,953,651 $ 5.40 [1] Issued 613,805 4.00 Exercised (50,000 ) 3.50 Expired (3,500 ) 30.00 Outstanding, March 31, 2017 3,513,956 $ 5.03 3.4 $ 430,902 Exercisable, March 31, 2017 3,513,956 $ 5.03 3.4 $ 430,902 [1] Excludes the impact of a warrant to purchase 35,000 shares of common stock that had an exercise price which was the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability was subject to satisfaction of certain performance criteria which had not occurred as of December 31, 2016. As discussed above under Warrant Modification and Exercise; the performance criteria were eliminated and the exercise price was reduced to $3.50 per share in consideration of the full exercise of the warrant by the holder. The following table presents information related to stock warrants at March 31, 2017: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $4.00 - $4.99 2,168,050 3.6 2,168,050 $5.00 - $5.99 1,169,243 3.2 1,169,243 $6.00 - $7.99 40,000 3.3 40,000 $8.00 - $9.99 2,500 2.7 2,500 $10.00 - $14.99 55,446 3.0 55,446 $15.00 - $19.99 38,559 2.4 38,559 $20.00 - $80.00 40,158 0.7 40,158 3,513,956 3.4 3,513,956 Stock Options On February 14, 2017, the Compensation Committee reduced the exercise price of outstanding options for the purchase of an aggregate of 1,219,450 shares of common stock of the Company (with exercise prices ranging between $5.70 and $30.00 per share) to $4.70 per share, which was the closing price for the Company’s common stock on February 13, 2017, as reported by the OTCQB. The exercise price reduction related to options held by, among others, the Company’s executive officers and directors. The incremental value of the modified options compared to the original options, both valued as of the respective modification date, of $430,394 is being recognized over the vesting term of the options. The following table presents information related to stock options at March 31, 2017: Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $3.10 - $3.99 857,000 9.2 197,336 $4.00 - $4.99 1,234,450 7.0 882,617 $5.00 - $5.99 5,000 7.2 5,000 $6.00 - $19.99 37,500 6.8 37,500 $20.00 - $30.00 35,000 5.0 35,000 2,168,950 7.3 1,157,453 The following table presents information related to stock option expense: Weighted Average Remaining For the Period Ended Unrecognized at Amortization March 31, March 31, Period 2017 2016 2017 (Years) Consulting $ 268,614 $ 104,094 $ 752,638 1.2 Research and development 258,416 100,502 781,361 1.8 General and administrative 387,600 140,329 884,526 1.3 $ 914,630 $ 344,925 $ 2,418,525 1.4

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 8 - Subsequent Events Notes Payable Subsequent to March 31, 2017, the Company issued notes payable with an aggregate principal amount of $255,000 for aggregate cash consideration of $225,000 which bears interest at rates ranging from 0% to 10% per annum payable at maturity. The $30,000 difference between the principal amount of the promissory notes and the cash received was recorded as an original issue discount and will be amortized to interest expense over the term of the note. In connection with the issuance of these promissory notes, the Company issued five-year, immediately vested warrants to purchase an aggregate of 20,000 shares of common stock at an exercise price of $4.00 per share. Subsequent to March 31, 2017, the Company issued a convertible note in the principal amount of $100,000 which bears interest at a rate of 10% per annum. The convertible note is payable as follows: (i) $25,000 of principal and the respective accrued interest on such principal is payable six months from the issuance date (the “First Maturity Date”), (ii) $25,000 of principal and the respective accrued interest on such principal is payable two weeks following the First Maturity Date, (iii) $25,000 of principal and the respective accrued interest on such principal is payable four weeks following the First Maturity Date, and (iv) $25,000 of principal and the respective accrued interest on such principal is payable six weeks following the First Maturity Date. Each payment of principal and the respective accrued interest is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to 60% of the fair market value of the Company’s stock; however, in no event shall the conversion price be less than $1.00. Should the Company elect to convert any of the note principal and respective accrued interest, the holder will have the right to accelerate the conversion of the remaining outstanding principal and accrued interest of the note at the same conversion price. The Company will recognize the beneficial conversion feature of the note as debt discount at the time the contingently adjustable conversion ratio is resolved. In connection with the issuance of this promissory note, the Company issued the lender 8,000 shares of common stock. Subsequent to March 31, 2017, the Company elected to convert certain convertible notes with an aggregate principal balance of $68,750 and accrued interest of $3,425 into an aggregate of 27,999 shares of common stock at conversion prices ranging from $2.56 to $2.70 per share. Subsequent to March 31, 2017, the Company and a certain lender agreed to exchange a certain note payable with a principal balance of $50,000 and accrued interest of $2,712 into 29,280 shares of common stock at an exchange price of $1.80 per share. Subsequent to March 31, 2017, the Company and certain lenders agreed to extend the maturity date of notes payable with an aggregate principal balance of $478,000 from maturity dates ranging between February 2017 to April 2017 to new maturity dates ranging from June 2017 to October 2017. In connection with one of the extensions, the Company issued the lender a five-year, immediately vested warrant to purchase 15,000 shares of common stock at an exercise price of $5.00 per share. Additionally, in connection with one of the extensions, the Company incurred an extension fee in the amount of $8,500 which was added to the principal balance of the note. In consideration of the extension and the cancellation of $21,250 of the principal amount of the note payable, the Company issued to the lender 7,000 shares of its common stock. Common Stock and Warrant Offerings Subsequent to March 31, 2017, the Company issued an aggregate of 18,000 shares of common stock and five-year immediately vested warrants to purchase an aggregate of 18,000 shares of common stock at an exercise price of $4.00 per share to investors for aggregate gross proceeds of $54,000 Compensation Subsequent to March 31, 2017, the Company extended their current agreement with a consultant from January 1, 2017 to June 30, 2017. In connection with this extension, the Company issued five-year immediately vested warrants to purchase 20,000 shares of common stock at an exercise price of $4.50 per share.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. As discussed above, Cayman, which had no material assets, liabilities or operations (other than intercompany balances) and is no longer needed to facilitate certain financings, was dissolved during the three months ended March 31, 2017.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Reclassification	Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net loss.
Concentrations	Concentrations One license and the related royalties comprised substantially all of the Company’s revenue during the three months ended March 31, 2017 and 2016. See Revenue Recognition below.
Revenue Recognition	Revenue Recognition The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after estimating potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. During the three months ended March 31, 2017 and 2016, the Company recognized revenue related to sales of Stem Pearls skincare products of $0 and $125, respectively. In November 2015, the Company and a stem cell treatment company (“SCTC”) entered into an amendment to a January 27, 2012 license agreement between them. Pursuant to the amendment, effective November 30, 2015, the Company granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States, certain intellectual property related to stem cell disc procedures (that originally was licensed to the Company by the SCTC pursuant to the January 27, 2012 license agreement). In consideration of the sublicense, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. During the three months ended March 31, 2017 and 2016, the Company recognized $7,000 and $9,000, respectively, of revenue related to the Company’s sublicense agreement.
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: March 31, 2017 2016 Options 2,168,950 1,345,450 Warrants 3,513,956 2,275,036 Convertible notes 136,360 68,467 Total potentially dilutive shares 5,819,266 3,688,953
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) are registered, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation – Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Schedule of Weighted Average Dilutive Common Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: March 31, 2017 2016 Options 2,168,950 1,345,450 Warrants 3,513,956 2,275,036 Convertible notes 136,360 68,467 Total potentially dilutive shares 5,819,266 3,688,953

Accrued Expenses and Other Cu17

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: March 31, 2017 December 31, 2016 Credit card payable $ 1,607 $ 1,778 Accrued payroll 888,387 1,105,293 Accrued research and development expenses 411,175 581,175 Accrued general and administrative expenses 318,893 263,468 Deferred rent 50,797 52,945 Total accrued expenses $ 1,670,859 $ 2,004,659

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule of Notes Payable Activity	A summary of the notes payable activity during the three months ended March 31, 2017 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, December 31, 2016 $ 697,500 $ 390,000 [1] $ 1,249,065 $ (179,964 ) $ 2,156,601 Issuances - - 242,000 - 242,000 Exchanges for equity (97,500 ) - (182,500 ) - (280,000 ) Conversions to equity - (65,000 ) - - (65,000 ) Repayments (50,000 ) - (24,000 ) - (74,000 ) Recognition of debt discount - - - (75,620 ) (75,620 ) Accretion of interest expense - - - 41,052 41,052 Amortization of debt discount - - - 132,742 132,742 Outstanding, March 31, 2017 $ 550,000 $ 325,000 [1] $ 1,284,565 $ (81,790 ) $ 2,077,775 [1] As of March 31, 2017 and December 31, 2016, a designated portion of convertible notes with an aggregate principal balance of $325,000 and $390,000, respectively, were convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $256,250 and $296,250 of principal into shares of common stock at March 31, 2017 and December 31, 2016, respectively, at the same conversion price.

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	3 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Schedule of Share Based Payment Award Stock Warrants Valuation Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Three Months Ended March 31, 2017 2016 Risk free interest rate 2.14% - 2.33 % 0.44% - 1.47 % Expected term (years) 5.00 0.67-5.00 Expected volatility 132 % 124 % Expected dividends 0.00 % 0.00 %
Schedule of Warrant Activity	A summary of the warrant activity during the three months ended March 31, 2017 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2016 2,953,651 $ 5.40 [1] Issued 613,805 4.00 Exercised (50,000 ) 3.50 Expired (3,500 ) 30.00 Outstanding, March 31, 2017 3,513,956 $ 5.03 3.4 $ 430,902 Exercisable, March 31, 2017 3,513,956 $ 5.03 3.4 $ 430,902 [1] Excludes the impact of a warrant to purchase 35,000 shares of common stock that had an exercise price which was the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability was subject to satisfaction of certain performance criteria which had not occurred as of December 31, 2016. As discussed above under Warrant Modification and Exercise; the performance criteria were eliminated and the exercise price was reduced to $3.50 per share in consideration of the full exercise of the warrant by the holder.
Schedule of Stock Warrant	The following table presents information related to stock warrants at March 31, 2017: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $4.00 - $4.99 2,168,050 3.6 2,168,050 $5.00 - $5.99 1,169,243 3.2 1,169,243 $6.00 - $7.99 40,000 3.3 40,000 $8.00 - $9.99 2,500 2.7 2,500 $10.00 - $14.99 55,446 3.0 55,446 $15.00 - $19.99 38,559 2.4 38,559 $20.00 - $80.00 40,158 0.7 40,158 3,513,956 3.4 3,513,956
Schedule of Stock Option	The following table presents information related to stock options at March 31, 2017: Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $3.10 - $3.99 857,000 9.2 197,336 $4.00 - $4.99 1,234,450 7.0 882,617 $5.00 - $5.99 5,000 7.2 5,000 $6.00 - $19.99 37,500 6.8 37,500 $20.00 - $30.00 35,000 5.0 35,000 2,168,950 7.3 1,157,453
Information Related to Stock Option Expense	The following table presents information related to stock option expense: Weighted Average Remaining For the Period Ended Unrecognized at Amortization March 31, March 31, Period 2017 2016 2017 (Years) Consulting $ 268,614 $ 104,094 $ 752,638 1.2 Research and development 258,416 100,502 781,361 1.8 General and administrative 387,600 140,329 884,526 1.3 $ 914,630 $ 344,925 $ 2,418,525 1.4

Going Concern and Management'20

Going Concern and Management's Plans (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital deficiency	$ 6,020,915
Stockholder's deficiency	4,721,666		$ 5,000,282
Net loss	2,785,754	$ 2,487,328
Proceeds from equity	54,000
Proceeds from debt	325,000
Amount of debt	140,000
Accrued interest	6,137
Repayments of debt	462,250
Note payable past due	$ 252,500

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Stem Pearls Skincare Products [Member]
Revenues	$ 0	$ 125
Sublicense Agreement [Member]
Deferred revenue recognized	$ 7,000	$ 9,000

Summary of Significant Accoun22

Summary of Significant Accounting Policies - Schedule of Weighted Average Dilutive Common Shares (Details) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Total potentially dilutive shares	5,819,266	3,688,953
Options [Member]
Total potentially dilutive shares	2,168,950	1,345,450
Warrants [Member]
Total potentially dilutive shares	3,513,956	2,275,036
Convertible Notes [Member]
Total potentially dilutive shares	136,360	68,467

Accrued Expenses and Other Cu23

Accrued Expenses and Other Current Liabilities (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Proceeds from related party notes	$ 30,015	$ 46,030
Repayment of advances from director and officer	$ 45,015	104,560
Warrants to purchase common stock	313,335
Exercise price per share	$ 4
Loss on extinguishment of notes payable, net	$ (61,340)	$ (11,847)
Exchange Agreement[Member]
Debt conversion, converted instrument, shares issued	10,000
Warrants to purchase common stock	10,000
Exercise price per share	$ 4
Common stock and warrants aggregate grant date value	$ 36,300
Loss on extinguishment of notes payable, net	6,300
Exchange Agreement[Member] | Chairman [Member]
Accrued consulting fees	$ 175,000
Debt conversion, converted instrument, shares issued	58,334
Warrants expiration period	5 years
Warrants to purchase common stock	58,334
Exercise price per share	$ 4
Common stock and warrants aggregate grant date value	$ 211,752
Loss on extinguishment of notes payable, net	$ 36,752
Exchange Agreement[Member] | Four Non-Employee Directors [Member]
Debt conversion, converted instrument, shares issued	88,334
Warrants expiration period	5 years
Warrants to purchase common stock	88,334
Exercise price per share	$ 4
Common stock and warrants aggregate grant date value	$ 320,652
Loss on extinguishment of notes payable, net	55,652
Accrued expenses, non-current portion	265,000
Non-Interest Bearing Advance [Member]
Proceeds from related party notes	30,015
Repayment of advances from director and officer	$ 45,015

Accrued Expenses and Other Cu24

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - Accrued Expenses and Other Current Liabilities [Member] - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Accrued Expenses and Other Current Liabilities [Line Items]
Credit card payable	$ 1,607	$ 1,778
Accrued payroll	888,387	1,105,293
Accrued research and development expenses	411,175	581,175
Accrued general and administrative expenses	318,893	263,468
Deferred rent	50,797	52,945
Total accrued expenses	$ 1,670,859	$ 2,004,659

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jan. 03, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Debt instrument, face amount		$ 325,000		$ 390,000
Amortization of debt discount		$ 132,742	$ 337,021
Warrants to purchase common stock		313,335
Common stock an exercise price per share		$ 4
Loss on extinguishment of note payables, net		$ 61,340	$ 11,847
Repayments of debt		462,250
Convertible Notes [Member]
Debt Instrument [Line Items]
Amortization of debt discount
Aggregate principal amount		65,000
Accrued interest		$ 3,411
Debt conversion, converted instrument, shares issued		26,207
Convertible Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price		$ 2.51
Debt instrument maturity date		Mar. 31, 2017
Convertible Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price		$ 2.77
Debt instrument maturity date		Apr. 30, 2017
Notes Payable [Member]
Debt Instrument [Line Items]
Repayments of debt		$ 74,000
Lender [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 242,000
Debt outstanding principal balance	200,000
Amortization of debt discount	$ 42,000
Warrant issued term	5 years	5 years
Warrants to purchase common stock	20,000	95,802
Common stock an exercise price per share	$ 4	$ 4
Fair value of warrant	$ 28,730
Aggregate principal amount		$ 280,000
Accrued interest		$ 7,402
Debt conversion, converted instrument, shares issued		95,802
Lender [Member] | Notes Payable [Member]
Debt Instrument [Line Items]
Warrant issued term		5 years
Warrants to purchase common stock		3,000
Common stock an exercise price per share		$ 4
Fair value of warrant		$ 4,890
Aggregate principal amount		$ 322,000
One Lender [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock		18,000
Common stock an exercise price per share		$ 4
Class of warrant or rights expiration date		Feb. 8, 2022
Common stock aggregate exchange date fair value		$ 348,742
Loss on extinguishment of note payables, net		$ 61,340

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable Activity (Details) - USD ($)		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Outstanding		$ 2,156,601
Issuances		242,000
Exchanges to equity		(280,000)
Conversion to equity		(65,000)
Repayments		(74,000)	$ (103,500)
Recognition of debt discount		(75,620)
Accretion of interest expense		41,052	2,916
Amortization of debt discount		132,742	$ 337,021
Outstanding		2,077,775
Debt Discount [Member]
Outstanding		(179,964)
Issuances
Exchanges to equity
Conversion to equity
Repayments
Recognition of debt discount		(75,620)
Accretion of interest expense		41,052
Amortization of debt discount		132,742
Outstanding		(81,790)
Convertible Notes [Member]
Outstanding	[1]	390,000
Issuances
Exchanges to equity
Conversion to equity		(65,000)
Repayments
Recognition of debt discount
Accretion of interest expense
Amortization of debt discount
Outstanding	[1]	325,000
Other Notes [Member]
Outstanding		1,249,065
Issuances		242,000
Exchanges to equity		(182,500)
Conversion to equity
Repayments		(24,000)
Recognition of debt discount
Accretion of interest expense
Amortization of debt discount
Outstanding		1,284,565
Related Party Notes [Member]
Outstanding		697,500
Issuances
Exchanges to equity		(97,500)
Conversion to equity
Repayments		(50,000)
Recognition of debt discount
Accretion of interest expense
Amortization of debt discount
Outstanding		$ 550,000
[1]	As of March 31, 2017 and December 31, 2016, a designated portion of convertible notes with an aggregate principal balance of $325,000 and $390,000, respectively, were convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $256,250 and $296,250 of principal into shares of common stock at March 31, 2017 and December 31, 2016, respectively, at the same conversion price.

Notes Payable - Schedule of N27

Notes Payable - Schedule of Notes Payable Activity (Details) (Parenthetical) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Debt instrument, face amount	$ 325,000	$ 390,000
Debt conversion, converted instrument, amount	65,000
Maximum [Member]
Debt conversion, converted instrument, amount	$ 256,250	$ 296,250

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Warrant term	5 years
Warrants to purchase common stock	313,335
Exercise price per share	$ 4
Loss on settlement of notes payable, net	$ (61,340)	$ (11,847)
Rent expense	32,000	$ 33,000
Employment Agreement [Member]
Bonus payments	255,000		$ 191,000
Employment Agreement [Member] | 2016 Bonus Milestones Achieved [Member]
Bonus payments	53,000		$ 100,000
Employment Agreement [Member] | January 31, 2017 to July 31, 2017 [Member] | 2016 Bonus Milestones Achieved [Member]
Bonus payments	99,000
Employment Agreement [Member] | Maximum [Member] | December 31, 2017 [Member]
Cash bonuses	402,500
Employment Agreement [Member] | Maximum [Member] | December 31, 2016 [Member]
Cash bonuses	$ 345,250
February 2011 Agreement[Member]
Agreement expiration date	Dec. 31, 2017
Consulting Agreement [Member]
Warrant term	5 years
Warrants to purchase common stock	25,000
Exercise price per share	$ 4
Fair value of warrant	$ 40,763
Exchange Agreement[Member]
Warrant term	5 years
Warrants to purchase common stock	10,000
Exercise price per share	$ 4
Consulting expense	$ 30,000
Debt conversion, converted instrument, shares issued	10,000
Common stock and warrants aggregate grant date value	$ 36,300
Loss on settlement of notes payable, net	$ 6,300

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	Feb. 14, 2017	Mar. 31, 2017	Mar. 31, 2016
Number of common stock issued		303,335
Warrant term		5 years
Warrants to purchase common stock		313,335
Exercise price per share		$ 4
Gross proceeds from warrants		$ 910,000
Warrants grant date fair value		510,735
Warrant modification charge		$ 4,500	$ 28,486
Weighted average estimated fair value of the warrants granted		$ 1.63	$ 0.89
Stock based compensation expenses		$ 955,393	$ 411,618
Warrant Modification and Exercise [Member]
Warrants to purchase common stock		50,000
Gross proceeds from warrants		$ 175,000
Stock Warrants [Member]
Stock based compensation expenses		$ 40,763	$ 0
Stock Options [Member]
Warrants to purchase common stock	1,219,450
Exercise price per share	$ 5.70
Stock options modification value	$ 430,394
Tranches [Member] | Warrant Modification and Exercise [Member]
Warrants to purchase common stock		35,000
Minimum [Member] | Warrant Modification and Exercise [Member]
Exercise price per share		$ 3.50
Minimum [Member] | Stock Options [Member]
Exercise price per share	$ 4.70
Maximum [Member] | Warrant Modification and Exercise [Member]
Exercise price per share		$ 30
Maximum [Member] | Stock Options [Member]
Exercise price per share	$ 30
Warrant And Option Valuation [Member] | Minimum [Member]
Estimated forfeitures related to option grants at an annual rate		0.00%
Warrant And Option Valuation [Member] | Maximum [Member]
Estimated forfeitures related to option grants at an annual rate		5.00%

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Share based Payment Award Warrants Valuation Assumptions (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Expected term (years)	5 years
Expected volatility	132.00%	124.00%
Expected dividends	0.00%	0.00%
Minimum [Member]
Risk free interest rate	2.14%	1.47%
Expected term (years)		5 years
Maximum [Member]
Risk free interest rate	2.33%	0.44%
Expected term (years)		8 months 1 day

Stockholders' Deficiency - Summ

Stockholders' Deficiency - Summary of Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Number of Warrants Exercisable, Balance	1,157,453
Warrant [Member]
Number of Warrants Outstanding, Beginning Balance	2,953,651
Number of Warrants Outstanding, Issued	613,805
Number of Warrants Outstanding, Exercised	(50,000)
Number of Warrants Outstanding, Expired	(3,500)
Number of Warrants Outstanding, Ending Balance	3,513,956
Number of Warrants Exercisable, Balance	3,513,956
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 5.40	[1]
Weighted Average Exercise Price Outstanding, Issued | $ / shares	4
Weighted Average Exercise Price Outstanding, Exercised | $ / shares	3.50
Weighted Average Exercise Price Outstanding, Expired | $ / shares	30
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	5.03
Weighted Average Exercise Price Exercisable, Balance | $ / shares	$ 5.03
Weighted Average Remaining Life In Years Outstanding	3 years 4 months 24 days
Weighted Average Remaining Life In Years Exercisable	3 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding | $	$ 430,902
Aggregate Intrinsic Value, Exercisable | $	$ 430,902
[1]	Excludes the impact of a warrant to purchase 35,000 shares of common stock that had an exercise price which was the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability was subject to satisfaction of certain performance criteria which had not occurred as of December 31, 2016. As discussed above under Warrant Modification and Exercise; the performance criteria were eliminated and the exercise price was reduced to $3.50 per share in consideration of the full exercise of the warrant by the holder.

Stockholders' Deficiency - Su32

Stockholders' Deficiency - Summary of Warrant Activity (Details) (Parenthetical)	Mar. 31, 2017$ / sharesshares
Exercise price per share	$ 4
Warrant Exercises [Member] | Minimum [Member]
Exercise price per share	$ 3.50
Warrant [Member]
Warrants to purchase shares of common stock | shares	35,000
Exercise price per share	$ 30

Stockholders' Deficiency - Sc33

Stockholders' Deficiency - Schedule of Stock Warrant (Details)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	3,513,956
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	3,513,956
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,168,050
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants	2,168,050
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	1,169,243
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	1,169,243
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	40,000
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	40,000
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,500
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	2,500
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	55,446
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years
Warrants Exercisable, Exercisable Number of Warrants	55,446
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	38,559
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	38,559
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	40,158
Warrants Exercisable, Weighted Average Remaining Life In Years	8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	40,158
Minimum [Member] | Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4
Minimum [Member] | Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	5
Minimum [Member] | Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	6
Minimum [Member] | Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	8
Minimum [Member] | Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	10
Minimum [Member] | Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	15
Minimum [Member] | Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	80
Maximum [Member] | Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	4.99
Maximum [Member] | Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	5.99
Maximum [Member] | Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	7.99
Maximum [Member] | Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	9.99
Maximum [Member] | Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	14.99
Maximum [Member] | Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	19.99
Maximum [Member] | Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 20

Stockholders' Deficiency - Sc34

Stockholders' Deficiency - Schedule of Stock Options (Details)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	2,168,950
Options Exercisable, Weighted Average Remaining Life In Years	7 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	1,157,453
Exercise Price One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	857,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	197,336
Exercise Price One [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 3.10
Exercise Price One [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 3.99
Exercise Price Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	1,234,450
Options Exercisable, Weighted Average Remaining Life In Years	7 years
Options Exercisable, Exercisable Number of Options	882,617
Exercise Price Two [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 4
Exercise Price Two [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 4.99
Exercise Price Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	5,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	5,000
Exercise Price Three [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 5
Exercise Price Three [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 5.99
Exercise Price Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	37,500
Options Exercisable, Weighted Average Remaining Life In Years	6 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	37,500
Exercise Price Four [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 6
Exercise Price Four [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 19.99
Exercise Price Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	35,000
Options Exercisable, Weighted Average Remaining Life In Years	5 years
Options Exercisable, Exercisable Number of Options	35,000
Exercise Price Five [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 20
Exercise Price Five [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 30

Stockholders' Deficiency - Info

Stockholders' Deficiency - Information Related to Stock Option Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Options [Member]
Unrecognized expense	$ 2,418,525
Option [Member]
Stock-based compensation expense	$ 914,630	$ 344,925
Weighted Average Remaining Amortization Period	1 year 4 months 24 days
Consulting [Member] | Options [Member]
Stock-based compensation expense	$ 268,614
Weighted Average Remaining Amortization Period	1 year 2 months 12 days
Consulting Expense [Member] | Options [Member]
Stock-based compensation expense		104,094
Unrecognized expense	$ 752,638
Research and Development Expense [Member] | Options [Member]
Stock-based compensation expense	258,416	100,502
Unrecognized expense	$ 781,361
Weighted Average Remaining Amortization Period	1 year 9 months 18 days
General and Administrative Expense [Member] | Options [Member]
Stock-based compensation expense	$ 387,600	$ 140,329
Unrecognized expense	$ 884,526
Weighted Average Remaining Amortization Period	1 year 3 months 18 days

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2017	Dec. 31, 2016	Jan. 03, 2017
Notes payable	$ 2,077,775	$ 2,077,775	$ 2,156,601
Warrant exercise price	$ 4	$ 4
Number of common stock issued		303,335
Aggregate principal amount	$ 325,000	$ 325,000	390,000
Debt instruments conversion amount		65,000
Gross proceeds from warrant		910,000
Maximum [Member]
Debt instruments conversion amount		$ 256,250	$ 296,250
Lender [Member]
Warrant exercise price	$ 4	$ 4		$ 4
Aggregate principal amount				$ 242,000
Accrued interest	$ 7,402	$ 7,402
Debt instruments conversion into shares		95,802
Subsequent Event [Member]
Notes payable	255,000	$ 255,000
Proceeds form issuence of notes	225,000
Original issue discount	$ 30,000
Warrants vested term	5 years
Warrant to purchase common stock issued in period	20,000	20,000
Warrant exercise price	$ 4	$ 4
Subsequent Event [Member] | Convertible Notes [Member]
Debt instruments interest rate	10.00%	10.00%
Convertible notes payable	$ 100,000	$ 100,000
Percentage of conversion price equal to fair market value	60.00%	60.00%
Conversion price per share	$ 1	$ 1
Number of common stock issued		8,000
Subsequent Event [Member] | Six Months from Issuance of First Maturity Date [Member]
Convertible notes payable	$ 25,000	$ 25,000
Subsequent Event [Member] | Two Weeks Following First Maturity Date [Member]
Convertible notes payable	25,000	25,000
Subsequent Event [Member] | Four Weeks Following First Maturity Date [Member]
Convertible notes payable	25,000	25,000
Subsequent Event [Member] | Six Weeks Following First Maturity Date [Member]
Convertible notes payable	25,000	25,000
Subsequent Event [Member] | Convertible Note One [Member]
Aggregate principal amount	68,750	68,750
Accrued interest	3,425	$ 3,425
Debt instruments conversion into shares		27,999
Subsequent Event [Member] | Note Payable [Member]
Notes payable	$ 478,000	$ 478,000
Warrant exercise price	$ 5	$ 5
Number of common stock issued		15,000
Debt instruments conversion into shares		7,000
Debt maturity date description		June 2017 to October 2017
Extension fee		$ 8,500
Subsequent Event [Member] | Minimum [Member]
Debt instruments interest rate	0.00%	0.00%
Subsequent Event [Member] | Minimum [Member] | Convertible Note One [Member]
Conversion price per share	$ 2.56	$ 2.56
Subsequent Event [Member] | Maximum [Member]
Debt instruments interest rate	10.00%	10.00%
Subsequent Event [Member] | Maximum [Member] | Convertible Note One [Member]
Conversion price per share	$ 2.70	$ 2.70
Subsequent Event [Member] | Warrant [Member]
Warrants vested term		5 years
Warrant to purchase common stock issued in period	18,000	18,000
Warrant exercise price	$ 4	$ 4
Number of common stock issued		18,000
Gross proceeds from warrant		$ 54,000
Subsequent Event [Member] | Lender [Member]
Conversion price per share	$ 1.80	$ 1.80
Aggregate principal amount	$ 50,000	$ 50,000
Accrued interest	$ 2,712	$ 2,712
Debt instruments conversion into shares		29,280
Debt instruments conversion amount		$ 21,250
Subsequent Event [Member] | Current Agreement With Consultant From January 1, 2017 to June 30, 2017 [Member]
Warrants vested term		5 years
Warrant to purchase common stock issued in period	20,000	20,000
Warrant exercise price	$ 4.50	$ 4.50